Noreddin Ayman M, El-Khatib Walid F, Aolie Jason, Salem Ahmed H, Zhanel George G
College of Pharmacy, University of Minnesota, 1110 Kirby Dr., Duluth, MN 55812, USA.
Int J Infect Dis. 2009 Jul;13(4):483-7. doi: 10.1016/j.ijid.2008.08.016. Epub 2008 Nov 28.
To compare the probability of target attainment (PTA) for macrolides and ketolides against penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae in both serum and epithelial lining fluid (ELF) of patients with community-acquired pneumonia (CAP).
Monte Carlo simulations were used to assess the attainment of the bacterial eradication-linked pharmacodynamic index of the free drug area under the concentration-time curve over 24 hours to minimum inhibitory concentration (fAUC(0-24)/MIC90) by azithromycin, clarithromycin, and telithromycin, at therapeutic doses, against penicillin-susceptible, intermediate, and resistant S. pneumoniae.
In serum, azithromycin and clarithromycin were found to have a probability of attaining the recommended fAUC(0-24)/MIC90 ratio of 30 in 50.2% and 74.6%, respectively, of CAP patients with penicillin-intermediate strains, and a probability of 36.9% and 60.7%, respectively, in cases of penicillin-resistant strains. Telithromycin maintained a probability of reaching the fAUC(0-24)/MIC90 ratio of 30 in serum and ELF in 89.1% of CAP patients, regardless of the penicillin resistance of the strain.
Clarithromycin results in a higher PTA than azithromycin in the treatment of penicillin-susceptible S. pneumoniae, but both of these agents exhibit a decreasing efficacy as S. pneumoniae penicillin resistance increases. When compared to clarithromycin and azithromycin, telithromycin maintains higher PTA in CAP patients with penicillin-resistant strains of S. pneumoniae.
比较大环内酯类和酮内酯类药物针对社区获得性肺炎(CAP)患者血清及上皮衬液(ELF)中对青霉素敏感、中介及耐药的肺炎链球菌的目标达成概率(PTA)。
采用蒙特卡洛模拟评估阿奇霉素、克拉霉素和泰利霉素在治疗剂量下针对对青霉素敏感、中介及耐药的肺炎链球菌,使24小时内游离药物浓度-时间曲线下面积与最低抑菌浓度的比值(fAUC(0 - 24)/MIC90)达到细菌清除相关药效学指标的情况。
在血清中,对于青霉素中介菌株的CAP患者,阿奇霉素和克拉霉素达到推荐的fAUC(0 - 24)/MIC90比值30的概率分别为50.2%和74.6%;对于青霉素耐药菌株,该概率分别为36.9%和60.7%。无论菌株对青霉素的耐药情况如何,泰利霉素在89.1%的CAP患者血清和ELF中达到fAUC(0 - 24)/MIC90比值30的概率保持不变。
在治疗对青霉素敏感的肺炎链球菌时,克拉霉素的PTA高于阿奇霉素,但随着肺炎链球菌对青霉素耐药性增加,这两种药物的疗效均降低。与克拉霉素和阿奇霉素相比,泰利霉素在患有青霉素耐药肺炎链球菌菌株的CAP患者中保持较高的PTA。